NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Price, News & Analysis

Achieve Life Sciences logo
$6.70 -0.08 (-1.11%)
Closing price 11/9/2026
Extended Trading
$6.70 0.00 (0.00%)
As of 11/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Achieve Life Sciences Stock (NASDAQ:ACHV)

Advanced

Key Stats

Today's Range
$6.52
▼
$6.91
50-Day Range
$6.38
▼
$8.12
52-Week Range
$2.62
▼
$8.64
Volume
1.09 million shs
Average Volume
1.36 million shs
Market Capitalization
$689.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Buy

Company Overview

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead candidate, cytisinicline, is an oral medication being studied to help people stop smoking and quit using nicotine-containing products, including e-cigarettes.

Cytisinicline is a plant-derived compound that acts on nicotinic receptors in the brain. Achieve is evaluating it in clinical trials; it is not an approved commercial product. The company’s development efforts have focused primarily on the U.S. market.

The company was formerly known as OncoGenex Pharmaceuticals and adopted the Achieve Life Sciences name as it shifted its focus to cytisinicline. Rick Stewart has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

Achieve Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ACHV MarketRank™: 
2.289676220805 of 5 stars

Achieve Life Sciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 560th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Achieve Life Sciences has a consensus price target of $15.50, representing about ∞ upside from its current price of $0.00.

  • Amount of Analyst Coverage

    Achieve Life Sciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Achieve Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.92) to ($0.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Achieve Life Sciences is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Achieve Life Sciences is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    17.94% of the float of Achieve Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Achieve Life Sciences has a short interest ratio ("days to cover") of 13.58, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Achieve Life Sciences has recently increased by 1.83%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Achieve Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Achieve Life Sciences does not have a long track record of dividend growth.

  • News Sentiment

    Achieve Life Sciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Achieve Life Sciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Achieve Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $175,115.00 in company stock.

  • Percentage Held by Insiders

    1.80% of the stock of Achieve Life Sciences is held by insiders.

  • Percentage Held by Institutions

    33.52% of the stock of Achieve Life Sciences is held by institutions.

  • Read more about Achieve Life Sciences' insider trading history.
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACHV Stock News Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Achieve Life Sciences Rebrands as AchieveRx, The Quit Company
See More Headlines

ACHV Stock Analysis - Frequently Asked Questions

Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.09.

Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020.The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional shareholders of Achieve Life Sciences include State Street Corp (3.61%), Simplify Asset Management Inc., Blue Owl Capital Holdings LP (0.40%) and Goldman Sachs Group Inc. (0.15%). Insiders that own company stock include Thomas Braxton King, Richard Alistair Stewart, Mark K Oki, Cindy Jacobs, Jaime Xinos and Jerry Wan.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Plug Power (PLUG), Gilead Sciences (GILD), Alibaba Group (BABA) and NIO (NIO).

Company Calendar

Last Earnings
11/10/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ACHV
CIK
949858
Employees
28
Year Founded
1995

Price Target and Rating

High Price Target
$19.00
Low Price Target
$12.00
Potential Upside/Downside
+131.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$54.65 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-511.12%
Return on Assets
-82.35%

Debt

Debt-to-Equity Ratio
0.87
Current Ratio
0.95
Quick Ratio
0.95

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
16.76

Miscellaneous

Outstanding Shares
102,902,000
Free Float
101,050,000
Market Cap
$689.96 million
Optionable
Optionable
Beta
2.42

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:ACHV) was last updated on 11/9/2026 by MarketBeat.com Staff.
From Our Partners